Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7951 to 8000 of 8211 results

  1. Kidney Cancer

    In development [GID-NG10398] Expected publication date: TBC

    NICE guideline
    In development

  2. Upadacitinib for treating giant cell arteritis [ID6299]

    Awaiting development [GID-TA11330] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Actim Pancreatitis for diagnosing acute pancreatitis

      Status ...

    Diagnostics guidance
    Topic selection

  4. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic

      Status ...

    Medical technologies guidance
    Topic selection

  5. PCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms

      Status ...

    Medical technologies guidance
    Topic selection

  6. Spartan RX point-of-care CYP2C19 test

      Status ...

    Diagnostics guidance
    Topic selection

  7. Healthy.io test for home testing of urine albumin to creatinine ratio

      Status ...

    Diagnostics guidance
    Topic selection

  8. FebriDx for C-reactive protein and myxovirus resistance protein A testing

      Status ...

    Diagnostics guidance
    Topic selection

  9. Helge for detecting haemolysis

      Status ...

    Diagnostics guidance
    Topic selection

  10. MolecuLight i:X for wound imaging

    The panel agreed the technology is not appropriate to be selected for guidance development as there is insufficient evidence.   ...

    Medical technologies guidance
    Topic selection

  11. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds

      Status ...

    Medical technologies guidance
    Topic selection

  12. Heart failure algorithms for remote monitoring in people with cardiac implantable electronic device: diagnostics consultation

    We are listening to your views on this Diagnostics guidance. Comments close 4 June 2024.

    Diagnostics guidance
    In consultation

  13. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]

    In development [GID-TA10813] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235

    In development [GID-TA11246] Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome: diagnostics consultation

    We are listening to your views on this Diagnostics guidance. Comments close 5 June 2024.

    Diagnostics guidance
    In consultation

  17. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development [GID-TA11086] Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Harmful gambling: identification, assessment and management

    In development [GID-NG10210] Expected publication date: 16 July 2024

    NICE guideline
    In development

  19. Older people

    All NICE products on older people. Includes any guidance, advice and quality standards.

    Topic page

  20. Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessment

    In development [GID-HTE10030] Expected publication date: 15 August 2024

    Health technology evaluations
    In development

  21. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441

    Awaiting development [GID-TA11544] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  22. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: TBC

    Technology appraisal guidance
    In development

  23. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    Awaiting development [GID-TA11093] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  25. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442

    Awaiting development [GID-TA11424] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  26. Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID6325]

    In development [GID-TA11545] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  27. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development [GID-TA11455] Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Adalimumab for treating early Dupuytren's contracture TS ID 11870

    Awaiting development [GID-TA11363] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  29. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 10 June 2024.

    Technology appraisal guidance
    In consultation

  30. Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]

    Awaiting development [GID-TA11346] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]

    Awaiting development [GID-TA11511] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  32. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

    Technology appraisal guidance
    In development

  33. Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]

    Awaiting development [GID-TA11248] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  34. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  35. Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]

    In development [GID-TA10778] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  36. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development [GID-TA11523] Expected publication date: TBC

    Technology appraisal guidance
    In development

  37. Type 2 diabetes in adults: management (medicines update)

    In development [GID-NG10336] Expected publication date: 19 June 2025

    NICE guideline
    In development

  38. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued [GID-IP2806]

    Interventional procedures guidance
    Discontinued

  39. MRI guided focussed ultrasound for chronic pain

    Discontinued [GID-IP1043]

    Interventional procedures guidance
    Discontinued

  40. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  41. Surgical correction of hallux valgus using minimal access techniques

    In development [GID-IPG10339] Expected publication date: 20 June 2024

    Interventional procedures guidance
    In development

  42. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Suspected cancer update

    In development [GID-QS10176] Expected publication date: TBC

    Quality standard
    In development

  44. Lung transplantation with ex-vivo perfusion

    Discontinued [GID-IP1046]

    Interventional procedures guidance
    Discontinued

  45. MT547 QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

      Status ...

    Medical technologies guidance
    Topic selection

  46. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Awaiting development [GID-TA11008] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  48. NVK-002 for treating myopia in people 3 to 17 years TSID 11961

      Status ...

    Technology appraisal guidance
    Topic selection

  49. Dapagliflozin for treating chronic kidney disease [ID6411]

    In development [GID-TA11547] Expected publication date: 12 February 2025

    Technology appraisal guidance
    In development

  50. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

    In development [GID-TA11513] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development